-
Mashup Score: 17PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY... by P. Connor Johnson - 2 day(s) ago
EHA Library; Johnson P. Jun 14 2025; 4160972;
Source: library.ehaweb.orgCategories: General Medicine NewsTweet
-
Mashup Score: 9
With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology’s latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric care.Read the full series here:https://www.thelancet.com/series-do/adverse-events-in-haematology-oncology?dgcid=buzzsprout_icw_podcast_13-06-25_lanhaeadverseevents25_lanhae
Source: www.buzzsprout.comCategories: General Medicine NewsTweet-
If you want to hear more from the authors of the first set of commission manuscripts, our @TheLancetHaem podcast is now online! https://t.co/Qs1hMNZ3SB ft. @GitaThanaMD @BiostatGirl @BroeckelmannPJ #EHA2025 https://t.co/zJzKUYV9Wd
-
-
Mashup Score: 45Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time? - 2 month(s) ago
Leukemia – Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Source: www.nature.comCategories: General Medicine NewsTweet-
2nd myeloid cancers post CD19 CAR @NGazeau14 - 539 pts, all B-NHL - 2-yr cumulative risk t-MN: 4.5% (10% at 4 yrs!) - ⬆️ MCV & high-grade ICANS risk factors for t-MN - 86% of t-MN had pre-CAR mutations Important retrospective study for #tcellrx. #lymsm https://t.co/hdKyrcHPPA https://t.co/Sgj35gvm2s
-
-
Mashup Score: 8Research Groups (Work-in-Progress, or WIPs) - 2 month(s) ago
ACCORDS hosts several works in progress groups to facilitate meeting and collaboration around these specific topic areas in health services research. ACCORDS provides meeting space and basic room scheduling assistance. If you are interested in having your group meet at ACCORDS, please reach out to Rebecca Howard Lead – Allison Kempe, MD, MPH Description: The Health Services Research (HSR) Work-in-Progress (WIP) has existed to support HSR researchers for over 20 years and brings together senior and junior
Source: medschool.cuanschutz.eduCategories: General Medicine NewsTweet-
Our imPROve Working Group meeting today to discuss a new patient-reported outcomes (PRO) instrument by @CUDeptSurg. imPROve is a think tank of PRO methodologists across @CUAnschutz who can help develop your studies; contact us if interested in presenting: https://t.co/QYz02HS8t7 https://t.co/6WXSKjCkXm
-
-
Mashup Score: 57
Venetoclax showed promising activity in a small phase II trial in relapsed/refractory Waldenström macroglobulinemia (WM). To report the clinical activity of venetoclax and prognostic factors associated with outcomes in a larger cohort, we …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
Venetoclax R/R Waldenstrom @YazeedSawalha: - 76 pts, mLOT 3, 82% prior cBTKi - 2-yr PFS 57%, OS 82% - med time to response 4 mos - no diff in 400 mg vs 800 mg ven - MV model: prior BTKi = ⬇️ PFS; >3 LOT = ⬇️ OS Thanks for opportunity to contribute! #lymsm https://t.co/373BF8paYk https://t.co/ADpYJ8Zh1S
-
-
Mashup Score: 60
Key PointsIbrutinib and nivolumab showed a response rate of 78% and the best complete response rate was 50% for relapsed/refractory CNS lymphomas.
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Ibrutinib+nivo in R/R CNS lymphoma - 18 pts: 16 PCNSL, 2 SCNSL, none concurrent systemic dx, 11 non-GC - ORR 78%, CR 50% (non-GC: ORR 91%, CR 45%) - 1-yr PFS 42%, OS 63%, 3 pts in remission for >2 yrs - 55% irAEs Bridging option to consolidation? #lymsm https://t.co/TlQKoexsfr https://t.co/3FnEUn1L2d
-
-
Mashup Score: 18Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN - 2 month(s) ago
Key Points. Acalabrutinib-obinutuzumab results in significantly higher PFS and OS vs chemoimmunotherapy regardless of high-risk features in TN CLLAcalabrut
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Acala+obin 6-yr F/U in 1L CLL - 535 pts randomized to AO, A or CIT - 6-yr PFS 78% AO, 62% A, 17% CIT - no diff in PFS for AO v A if uIGHV - no diff in OS for AO v A (6-yr OS 84% AO, 76% A) Less G3+ AEs with A monotherapy. How much does obinu add? #lymsm https://t.co/uwZsRlV7Zt https://t.co/pdB6yoEf0Z
-
-
Mashup Score: 60
Key PointsIbrutinib and nivolumab showed a response rate of 78% and the best complete response rate was 50% for relapsed/refractory CNS lymphomas.
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Ibrutinib+nivo in R/R CNS lymphoma - 18 pts: 16 PCNSL, 2 SCNSL, none concurrent systemic dx, 11 non-GC - ORR 78%, CR 50% (non-GC: ORR 91%, CR 45%) - 1-yr PFS 42%, OS 63%, 3 pts in remission for >2 yrs - 55% irAEs Bridging option to consolidation? #lymsm https://t.co/TlQKoexsfr https://t.co/3FnEUn1L2d
-
-
Mashup Score: 11The Perfect Doctor - 2 month(s) ago
The Perfect Doctor: Forty Voices on the Imperfect Pursuit of an Ideal
Source: theperfectdoctor.orgCategories: General Medicine NewsTweet-
Our latest print book "The Perfect Doctor" is on sale at a 20% discount until April 22! Learn more about the compilation at https://t.co/lrMTnGqYlp. All book proceeds go to support the website hosting costs of our publications at https://t.co/KSO4dutB64. https://t.co/HQM6bcVq0d https://t.co/anvVbjUt4q
-
-
Mashup Score: 4
Published in Leukemia & Lymphoma (Ahead of Print, 2025)
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet-
"A diagnosis of NLPHL is often a long, confusing, and isolating journey." Our @glow_nlphl study of patient & care partner perspectives on NLPHL, and how we can better counsel on management options. Many thanks to our collaborating patient advocates. #lymsm https://t.co/vPNX1L6JPu https://t.co/5Hi8jKn2gY
-
Folks at #EHA2025: check out our poster (PS1898) on PROs in EPCORE NHL-1. Patients with R/R FL who had 3+ symptoms at baseline had clinically-meaningful improvements in lymphoma-related symptoms that continued to improve after epco initiation. https://t.co/mp4IEMFpRS https://t.co/F3lB2YWgz5